- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01802073
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects (PSC)
Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate changes in the fecal and salivary/urinary microbiota during vancomycin treatment of children and adults with Primary Sclerosing Cholangitis (PSC), identify features of the host microbiota that are associated with disease activity and/or response to treatment and further delineate the immunological effects of oral vancomycin treatment of PSC. This study will correlate changes in microbiota with the immunological effects of oral vancomycin in children and adults with PSC. The results of this proposal will lead to new and validated targets for diagnosis and treatment of PSC that will have high impact in the short and long term for patients and their families.
Interim results were published in Abarbanel et al, J Clin Immunol 2013 (see References).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- PSC Diagnosis: Liver biopsy and/or imaging (MRCP, ERCP, CT, or US
- Colonoscopy within 1 year or starting of study
2 groups:
- IBD (Inflammatory bowel disease) and PSC: details of extent and type of IBD
- No IBD and PSC, but positive p-ANCA or ASCA serologies indicating possible IBD.
Exclusion Criteria:
- Allergy to Vancomycin
- PSC not associated with IBD or NO positive IBD antibodies (p-ANCA [anti- neutrophil cytoplasmic antibody] or ASCA [anti-Saccharomyces cerevisiae antibody])
- Cholangiocarcinoma
- On oral or topical (enemas or suppositories) corticosteroids,topical mesalamine, or biologics (infliximab, adalimumab, certolizumab).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral Vancomycin
1) For children who weight < or = 30 kg, the vancomycin dose will be 50 mg/kg/day given orally 3 times per day for the 1st month and continue with the same dose for subsequent months if the clinical laboratory studies improved and are normal.
If the laboratory studies are not normal the dose will be increased to 75 mg/kg/day given orally 3 times per day for the 2nd month and 100mg/kg/day given orally 3 times per day the 3rd month.
If the laboratory studies do not improve by the end of the 3rd month since starting the vancomycin, the vancomycin will be stopped and the child will not continue the study.
2) For adults and children who weigh >30 kg, the vancomycin dose will be 500 mg given orally 3 times per day for the 1st month and continue with this dose if the clinical laboratory studies improve and are normal.
If the laboratory studies are not normal the dose will be increased to 750 mg 3 times per day for the 2nd month and 1000 mg 3 times per day the 3rd month.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3
Time Frame: Baseline; Month 3
|
Clinically significant improvement was determined by investigator assessment per participant based on their medical history and disease stage.
Elevated ALT was any value greater than the upper limit of the standard reference range used by patient's laboratory.
|
Baseline; Month 3
|
Count of Participants With Elevated Gamma-glutamyltransferase (GGT) at Baseline and With Clinically Significant Improvement at Month 3
Time Frame: Baseline; Month 3
|
Clinically significant improvement was determined by investigator assessment per participant based on their medical history and disease stage.
Elevated GGT was any value greater than the upper limit of the standard reference range used by patient's laboratory.
|
Baseline; Month 3
|
Count of Participants With Elevated ALT and/or GGT at Baseline and With Clinically Significant Improvement at Month 3
Time Frame: Baseline; Month 3
|
Clinically significant improvement was determined by investigator assessment per participant based on their medical history and disease stage.
Elevated ALT (and GGT) was any value greater than the upper limit of the standard reference range used by patient's laboratory.
|
Baseline; Month 3
|
Count of Participants With Abnormal Magnetic Resonance Cholangiopancreatography (MRCP) Imaging at Baseline and With Clinically Significant Improvement at Year 1
Time Frame: Baseline; Year 1
|
Clinically significant improvement was determined by investigator assessment per participant based on their medical history and disease stage.
MRCP imaging was abnormal if it included biliary beading, biliary strictures, dilated bile duct, and/or liver fibrosis.
|
Baseline; Year 1
|
Count of Participants With Abnormal Liver Biopsies at Baseline and With Clinically Significant Improvement at Year 1
Time Frame: Baseline; Year 1
|
Clinically significant improvement was determined by investigator assessment per participant based on their medical history and disease stage.
Liver pathology was considered abnormal if the biopsy was S1 or greater on the liver fibrosis staging scale (S0 no fibrosis, S1 mild fibrosis, S2 moderate fibrosis, S3 sever fibrosis, S4 cirrhosis).
|
Baseline; Year 1
|
Count of Participants With Abnormal MRCP and/or Liver Biopsy at Baseline and With Clinically Significant Improvement at Year 1
Time Frame: Baseline; Year 1
|
Clinically significant improvement was determined by investigator assessment per participant based on their medical history and disease stage.
MRCP imaging was abnormal if it included biliary beading, biliary strictures, dilated bile duct, and/or liver fibrosis.
Liver pathology was considered abnormal if the biopsy was S1 or greater on the liver fibrosis staging scale (S0 no fibrosis, S1 mild fibrosis, S2 moderate fibrosis, S3 sever fibrosis, S4 cirrhosis).
|
Baseline; Year 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kenneth Cox, MD, Stanford University
Publications and helpful links
General Publications
- Abarbanel DN, Seki SM, Davies Y, Marlen N, Benavides JA, Cox K, Nadeau KC, Cox KL. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2013 Feb;33(2):397-406. doi: 10.1007/s10875-012-9801-1. Epub 2012 Oct 9.
- Ali AH, Damman J, Shah SB, Davies Y, Hurwitz M, Stephen M, Lemos LM, Carey EJ, Lindor KD, Buness CW, Alrabadi L, Berquist WE, Cox KL. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scand J Gastroenterol. 2020 Aug;55(8):941-950. doi: 10.1080/00365521.2020.1787501. Epub 2020 Jul 7.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22591
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Sclerosing Cholangitis
-
Medical University of WarsawNational Science Centre, PolandRecruitingPrimary Sclerosing Cholangitis (PSC)Poland
-
Mayo ClinicActive, not recruiting
-
Cascade Pharmaceuticals, IncCovanceCompletedPrimary Sclerosing Cholangitis (PSC)United States
-
HighTide Biopharma Pty LtdCompletedPrimary Sclerosing Cholangitis (PSC)United States, Canada
-
Intercept PharmaceuticalsCompletedPrimary Sclerosing Cholangitis (PSC)United States, Italy
-
Mirum Pharmaceuticals, Inc.CompletedPrimary Sclerosing Cholangitis (PSC)United States, United Kingdom, Canada
-
Mayo ClinicCompletedPrimary Sclerosing Cholangitis (PSC)United States
-
Gilead SciencesCompletedPrimary Sclerosing Cholangitis (PSC)United States, Belgium, Canada, Germany, United Kingdom, Italy, Spain, Denmark, Netherlands, Sweden
-
Brigham and Women's HospitalCompletedSclerosing CholangitisUnited States
-
Boston Scientific CorporationCompletedPrimary Sclerosing Cholangitis (PSC)United States, Canada, Netherlands, Norway
Clinical Trials on Oral Vancomycin
-
St. Luke's Hospital, Chesterfield, MissouriCompletedClostridium Difficile Infection | Prophylaxis | Vancomycin
-
University of Wisconsin, MadisonNational Institute of Allergy and Infectious Diseases (NIAID)CompletedClostridium Difficile Infection RecurrenceUnited States
-
University of MinnesotaRecruitingPrimary Sclerosing CholangitisUnited States
-
University of Nevada, RenoRenown Regional Medical CenterCompletedClostridium Difficile InfectionUnited States
-
Vedanta Biosciences, Inc.RecruitingUlcerative Colitis | Colitis, UlcerativeUnited States, Netherlands, Lithuania, Bulgaria, Hungary, Ukraine, Czechia, Poland, United Kingdom
-
Medical College of WisconsinCompletedClostridium Difficile InfectionUnited States
-
Astellas Pharma Europe B.V.Merck Sharp & Dohme LLCCompletedClostridium Difficile-associated Diarrhea (CDAD)United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
-
University Hospital Birmingham NHS Foundation TrustRecruitingInflammatory Bowel Diseases | Primary Sclerosing CholangitisUnited Kingdom
-
University of South FloridaTerminatedClostridium Difficile Infection | Clostridium Difficile Infection RecurrenceUnited States
-
Vedanta Biosciences, Inc.Completed